ABIVAX Société Anonyme Beheer

Beheer criteriumcontroles 1/4

De CEO ABIVAX Société Anonyme is Marc M. de Garidel, benoemd in May2023, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.061% van de aandelen van het bedrijf, ter waarde € 366.57K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.5 jaar en 4.8 jaar.

Belangrijke informatie

Marc M. de Garidel

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	0.06%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	4.8yrs

Recente managementupdates

Recent updates

CEO

Marc M. de Garidel (65 yo)

less than a year

Tenure

Mr. Marc M. P. de Garidel, M.B.A., serves as CEO & Interim Chair of Board at ABIVAX Société Anonyme since May 5, 2023. He has been the Chief Executive Officer of CinCor Pharma, Inc. since July 2021 and has...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Philippe Pouletty	Founder & Director	no data	geen gegevens	0.44% € 2.6m
Marc M. de Garidel	CEO & Interim Chair of Board	less than a year	geen gegevens	0.061% € 366.6k
Didier Blondel	EVP, CFO & Board Secretary	6.9yrs	geen gegevens	0.00060% € 3.6k
Didier Scherrer	Chief Scientific Officer	less than a year	geen gegevens	0.057% € 343.8k
Patrick Malloy	Senior Vice President of Investor Relations	less than a year	geen gegevens	geen gegevens
Ida Hatoum	Chief People Officer	less than a year	geen gegevens	geen gegevens
Pierre Courteille	Chief Business Officer	no data	geen gegevens	0% € 0
Jérôme Denis	Executive Vice President of Process Development & Manufacturing	less than a year	geen gegevens	geen gegevens
Sheldon Sloan	Chief Medical Officer	less than a year	geen gegevens	geen gegevens
Michael Ferguson	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens

0.5yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ABVXp wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.5 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Philippe Pouletty	Founder & Director	9yrs	geen gegevens	0.44% € 2.6m
Marc M. de Garidel	CEO & Interim Chair of Board	less than a year	geen gegevens	0.061% € 366.6k
Christian Brechot	Member of Scientific Advisory Board	6.2yrs	geen gegevens	geen gegevens
Christian Trepo	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Lawrence Stanberry	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Troy Ignelzi	Independent Director	less than a year	geen gegevens	geen gegevens
Christoph Huber	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Claude Bertrand	Member of Scientific Advisory Board	4.2yrs	€4.94k	geen gegevens
Luc Teyton	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
June Lee	Independent Director	less than a year	geen gegevens	geen gegevens
Corinna Bonsen-Thomas	Independent Non-Executive Director	6.5yrs	€22.89k	0% € 0
Ian McGowan	Chairman of Scientific Advisory Board	5.5yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ABVXp wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

ABIVAX Société Anonyme Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Abivax SA Announces Board Observer & Advisor Appointments

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Insufficient new directors

Insufficient new directors

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Insufficient new directors

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

Insufficient new directors

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

New 90-day high: €28.90

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd